-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2024-06-26
HLN:NYE- (USD)
COMMON STOCK | Drug Manufacturers - Specialty & Generic |
Last Closing
USD 8.5Change
-0.07 (-0.82)%Market Cap
USD 38.63BVolume
2.67M![](https://ducovest.com/tools/assets/assets/images/analyst-meter.png)
N/A
Verdict
Values as of: 2024-06-26
COMMON STOCK | Drug Manufacturers - Specialty & Generic |
Last Closing
USD 8.5Change
-0.07 (-0.82)%Market Cap
USD 38.63BVolume
2.67MN/A
Verdict
Currency: USD
Country : USA
Symbol | Name | Price(Change) | Market Cap |
---|---|---|---|
ZTS | Zoetis Inc |
-3.10 (-1.76%) |
USD 77.98B |
TAK | Takeda Pharmaceutical Co Ltd A.. |
+0.03 (+0.23%) |
USD 40.23B |
TEVA | Teva Pharma Industries Ltd ADR |
-0.01 (-0.06%) |
USD 19.41B |
RDY | Dr. Reddy’s Laboratories Ltd.. |
+0.79 (+1.05%) |
USD 11.98B |
CTLT | Catalent Inc |
-0.18 (-0.32%) |
USD 9.98B |
ELAN | Elanco Animal Health |
+0.16 (+1.12%) |
USD 8.97B |
PRGO | Perrigo Company PLC |
+0.25 (+0.98%) |
USD 3.59B |
PBH | Prestige Brand Holdings Inc |
-0.77 (-1.11%) |
USD 3.46B |
EVT | Eaton Vance Tax Advantaged Div.. |
+0.06 (+0.26%) |
USD 3.26B |
BHC | Bausch Health Companies Inc |
+0.08 (+1.16%) |
USD 2.51B |
Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
---|---|---|---|---|---|
DXSK:XETRA | Xtrackers - Stoxx Europe .. | 4.86 % | 0.00 % |
-1.88 (0.00%) |
USD 0.07B |
XS3R:LSE | Xtrackers MSCI Europe Con.. | 0.00 % | 0.00 % |
-163.00 (0.00%) |
USD 0.07B |
DXSK:F | Xtrackers - Stoxx Europe .. | 0.00 % | 0.00 % |
N/A |
USD 0.06B |
EXV4:F | iShares STOXX Europe 600 .. | 0.00 % | 0.00 % |
N/A |
USD 0.73B |
EXV4:XETRA | iShares STOXX Europe 600 .. | 0.00 % | 0.00 % |
-0.04 (0.00%) |
USD 0.70B |
FT1K:LSE | Amundi MSCI UK IMI SRI PA.. | 0.00 % | 0.00 % |
-5.10 (0.00%) |
N/A |
SXDPEX:SW | iShares STOXX Europe 600 .. | 0.00 % | 0.00 % |
N/A |
USD 0.44B |
Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) | Market Performance vs. Exchange | ||||||
Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
YTD | |||||||
Capital Gain | 3.28% | 50% | F | 56% | F | ||
Dividend Return | 1.29% | 50% | F | 39% | F | ||
Total Return | 4.57% | 56% | F | 54% | F | ||
Trailing 12 Months | |||||||
Capital Gain | 4.04% | 56% | F | 47% | F | ||
Dividend Return | 1.86% | 60% | D- | 28% | F | ||
Total Return | 5.90% | 50% | F | 41% | F | ||
Trailing 5 Years | |||||||
Capital Gain | N/A | N/A | N/A | N/A | N/A | ||
Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
Total Return | N/A | N/A | N/A | N/A | N/A | ||
Average Annual (5 Year Horizon) | |||||||
Capital Gain | 6.36% | 65% | D | 62% | D | ||
Dividend Return | 6.62% | 59% | D- | 55% | F | ||
Total Return | 0.26% | 20% | F | 6% | D- | ||
Risk Return Profile | |||||||
Volatility (Standard Deviation) | 12.42% | 94% | A | 71% | C- | ||
Risk Adjusted Return | 53.30% | 82% | B | 75% | C | ||
Market Capitalization | 38.63B | 88% | B+ | 94% | A |
Target Price Action | Rating Action | Analyst | Rating | Price | Date |
---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
This stock has shown below median earnings growth in the previous 5 years compared to its sector
This stock has shown below median revenue growth in the previous 5 years compared to its sector